SCPH (scPharmaceuticals) Short-Term Debt to Capital

scPharmaceuticals Inc. (SCPH) produces equipment for home therapy of cardiac pathologies, optimizing supply chains to grow operating profit. The company generates revenue from the sale of Furoscix systems, attracting insurance funds by reducing inpatient expenses. This chart of the individual debt-to-equity ratio is fixed at 0.00. The unique product allows the brand to effectively displace costly hospital treatment while maintaining high margins.

scPharmaceuticals Inc. is developing a high-tech ecosystem for the home treatment of heart failure through the integration of the Furoscix system. This indicator measures the proportion of current liabilities within the equity structure, revealing hidden financial degradation caused by the accumulation of short-term loans. An increase in this ratio signals a decline in the business's resilience to market shocks. By analyzing the change in short-term debt levels relative to equity, an investor determines the company's real margin of safety.